Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Treatment of Cancer-Associated Thrombosis 2.0
share announcement

Treatment of Cancer-Associated Thrombosis 2.0

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 3473

Special Issue Editors

Dr. Corinne Frere

E-Mail Website
Guest Editor
INSERM UMRS-1166, Institute of Cardiometabolism and Nutrition, GRC 27 GRECO, Sorbonne Université, F-75013 Paris, France
Interests: hemostasis; thrombosis; cancer-associated thrombosis; intensive care medicine; biomarkers; translational studies
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Dominique Farge

E-Mail Website
Guest Editor
1. Internal Medicine Unit (UF 04): CRMR MATHEC, Maladies Auto-Immunes et Thérapie Cellulaire, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, F-75010 Paris, France
2. Institut Universitaire d’Hématologie, Université de Paris, EA 3518, F-75010 Paris, France
Interests: venous thromboembolism; cancer; decision support systems; clinical practice guidelines; predictive medicine
Special Issues, Collections and Topics in MDPI journals
Dr. Jean M. Connors

E-Mail Website
Guest Editor
Hematology Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02215, USA
Interests: venous thromboembolism; cancer; decision support systems; clinical practice guidelines; predictive medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This collection is the second edition of a previous Special Issue on “Treatment of Cancer-Associated Thrombosis” (https://www.mdpi.com/journal/cancers/special_issues/Thrombo_sis).

Venous thromboembolism (VTE) is a common and life-threatening complication in cancer patients. Cancer patients often suffer from multiple co‐morbidities and have a greater risk of both VTE recurrence and bleeding compared to noncancer patients. For many years, long-term therapy with low-molecular-weight heparin (LMWH) has been the standard of care for the management of cancer-associated thrombosis (CAT), but recent randomized controlled trials have indicated that direct oral anticoagulants (DOAC) are also effective. With the emergence of DOAC as a new option in the treatment of CAT, clinicians are now facing a multitude of choices for each individual patient. A personalized approach matching the right drug to the right patient based on drug properties, efficacy, and safety, the side effect profile of each drug, and patient preference will thus probably supplant the one size fits all approach in the future. This Special Issue will cover the current clinical evidence supporting the standard of care and emerging treatment options for CAT. Data on adherence to CAT clinical practice guidelines and evidence on anticoagulant effects on quality-of-life perception in cancer patients will be also welcomed.

Dr. Corinne Frere
Prof. Dr. Dominique Farge
Dr. Jean M. Connors
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • venous thromboembolism
  • cancer
  • low-molecular-weight heparin
  • direct oral anticoagulant
  • cancer-associated thrombosis

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 441 KiB  
Article
Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs: Results from the RIETE Registry
by Philippe Debourdeau, Laurent Bertoletti, Carme Font, Juan José López-Núñez, Covadonga Gómez-Cuervo, Isabelle Mahe, Remedios Otero-Candelera, Maria Dolores Adarraga, Patricia López-Miguel, Manuel Monreal and RIETE Investigators
Cancers 2023, 15(7), 2034; https://doi.org/10.3390/cancers15072034 - 29 Mar 2023
Cited by 2 | Viewed by 1835
Abstract
Background: The clinical characteristics and outcomes of cancer patients with lower-limb isolated superficial vein thrombosis (SVT) have not been consistently evaluated. Methods: We used data in the RIETE registry to compare the clinical characteristics and 90-day outcomes for patients with: (1) active cancer [...] Read more.
Background: The clinical characteristics and outcomes of cancer patients with lower-limb isolated superficial vein thrombosis (SVT) have not been consistently evaluated. Methods: We used data in the RIETE registry to compare the clinical characteristics and 90-day outcomes for patients with: (1) active cancer and lower-limb SVT; (2) active cancer and lower-limb deep vein thrombosis (DVT); (3) lower-limb SVT without cancer. The primary outcomes included subsequent symptomatic SVT, DVT or pulmonary embolism (PE). Secondary outcomes were major bleeding and death. Results: From March 2015 to April 2021, there were 110 patients with cancer and SVT, 1695 with cancer and DVT, and 1030 with SVT but no cancer. Most patients in all subgroups (93%, 99% and 96%, respectively) received anticoagulants, while those with SVT received lower daily doses of low-molecular-weight heparin (114 ± 58, 163 ± 44, and 106 ± 50 IU/kg, respectively). During the first 90 days, 101 patients (3.6%) developed subsequent VTE (PE 47, DVT 41, SVT 13), whereas 72 (2.5%) had major bleeding and 282 (9.9%) died. Among the three groups, 90-day events were, respectively: VTE at rates of 7.3%, 4.0% and 2.4%; major bleeding at rates of 2.7%, 3.9% and 0.3%; mortality at rates of 8.2%, 16% and 0.3%. Between D90 and D180, only one SVT recurrence and one death occurred in SVT cancer patients. In multivariable analysis, cancer was associated with subsequent VTE (HR = 2.04; 1.15–3.62), while initial presentation as SVT or DVT were not associated with a different risk. Conclusions: The risk for subsequent VTE (including symptomatic SVT, DVT or PE) was similar in cancer patients with isolated SVT than in those with isolated DVT. Full article
(This article belongs to the Special Issue Treatment of Cancer-Associated Thrombosis 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 902 KiB  
Review
The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis
by Mariasanta Napolitano and Sergio Siragusa
Cancers 2023, 15(18), 4640; https://doi.org/10.3390/cancers15184640 - 20 Sep 2023
Cited by 1 | Viewed by 1187
Abstract
Cancer-associated thrombosis (CAT) is a leading cause of death among patients with cancer. CAT can manifest itself as venous thromboembolism (VTE), in the form of deep vein thrombosis or pulmonary embolism, or arterial thromboembolism. The pathophysiology of CAT is complex and depends on [...] Read more.
Cancer-associated thrombosis (CAT) is a leading cause of death among patients with cancer. CAT can manifest itself as venous thromboembolism (VTE), in the form of deep vein thrombosis or pulmonary embolism, or arterial thromboembolism. The pathophysiology of CAT is complex and depends on cancer-, patient-, treatment- and biomarkers-related factors. Treatment of VTE in patients with cancer is complex and includes three major classes of anticoagulant agents: heparin and its derivatives, e.g., low molecular weight heparins, direct oral anticoagulants (DOACs), and vitamin K inhibitors. Given the tremendous heterogeneity of clinical situations in patients with cancer and the challenges of CAT, there is no single universal treatment option for patients suffering from or at risk of CAT. Initial studies suggested that patients seemed to prefer an anticoagulant that would not interfere with their cancer treatment, suggesting the primacy of cancer over VTE, and favoring efficacy and safety over convenience of route of administration. Recent studies show that when the efficacy and safety aspects are similar, patients prefer the oral route of administration. Despite this, injectables are a valid option for many patients with cancer. Full article
(This article belongs to the Special Issue Treatment of Cancer-Associated Thrombosis 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop